ADARx’s $446m IPO signals investor appetite for next-gen RNA therapeutics
Why now
Thesis: RNA biotech IPO tests investor appetite
Catalyst to watch: Aftermarket performance and follow-on IPOs
Main risk: Single IPO may not signal a durable window
Why it matters
A $446m RNA-therapeutics IPO signals reopening investor appetite for biotech new issues.
Related assets & topics
HealthcareSources
- googlenews · news.google.com · 2026-09-29 11:09 UTC